Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Cencora, Inc. by Year
Cencora, Inc. — Share of U.S. Gross Product Sales (legacy disclosure) (%) (%)
Amgen Cencora, Inc.: 35.0% in FY2018, unchanged from a year earlier. No newer figure appears in the documents we track.
Latest, FY2018
35.0%
Period ended Dec 31, 2018
Change on a year earlier
0.0 pts
35.0% in FY2017
History
4 years
Since FY2015
Sources
2
Documents cited below
Where the FY2018 figure comes from
Source: Form 10-K (filed 2019-02-13) ↗
Reported in Form 10-K Note 1 Customer Concentration (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cencora, Inc. — Share of U.S. Gross Product Sales (legacy disclosure) (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | 35.0% | 0.0 pts | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 35.0% | +1.0 pts | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 34.0% | 0.0 pts | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 34.0% | – | Form 10-K (filed 2018-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Cencora, Inc. (%), annual FY2015–FY2018 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/conc-cencora-us-pct
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.